We need the development of new, complex biomarkers to address the increasing complexity in treatment modalities that, in and of themselves, have characteristics of a continuous variable; they require innovation and outcomes data, which perhaps will be partly addressed by some of the emerging real-world evidence databases amassed by pairing sequence information and clinical outcomes. Tumor mutational burden is a great example of this innovation in practice.
